TIMI Study Group, Brigham & Women's Hospital

350 Longwood Avenue
1st Office Floor
Boston,  MA  02115-5722

United States
  • Booth: 1028


The Thrombolysis in Myocardial Infarction (TIMI) Study Group, an academic research organization, was formed in 1984 with support from the National Heart, Lung, and Blood Institute. Its initial goal was to compare the effects of the then-new thrombolytic agent, recombinant tissue plasminogen activator, with streptokinase. TIMI has remained active since then and has completed 60+ multicenter clinical trials. The TIMI network now collaborates with more than 1000 separate sites in 45 countries on 5 continents. In addition to thrombolytic agents, TIMI has studied antithrombotic, antiplatelet, anti-ischemic, lipid lowering, and anti-inflammatory drugs. TIMI has also established robust biomarker & pharmacogenetics programs, and has devised a panel of risk assessment scores that are widely used.